Sumatrolide Solution dispersible tablets 250mg, No. 6

Infectious and inflammatory diseases caused by microorganisms sensitive to azithromycin, incl. bronchitis, pneumonia, infections of the skin and soft tissues, otitis media, sinusitis, pharyngitis, tonsillitis, gonorrheal and non-gonorrheal urethritis and / or cervicitis, Lyme disease (borreliosis).

Set individually, taking into account the nosological form, the severity of the course of the disease and the sensitivity of the pathogen.
For adults inside - 0.25-1 g 1 time / day; children - 5-10 mg / kg 1 time / day. Duration of admission is 2-5 days.

1 tab. contains:

Active substances:

azithromycin (in the form of a dihydrate) 250 mg

Excipients:

microcrystalline cellulose,

crospovidone,

pregelatinized starch,

blackcurrant flavoring,

magnesium stearate,

sodium saccharinate,

vanillin,

colloidal silicon dioxide.

Hypersensitivity to azithromycin and other macrolide antibiotics.

pharmachologic effect

An antibiotic of the macrolide group, is a representative of azalides. Suppresses RNA-dependent protein synthesis of sensitive microorganisms.
Active against gram-positive bacteria: Staphylococcus aureus, Streptococcus spp. (including Streptococcus pneumoniae, Streptococcus pyogenes / group A /); gram-negative bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus ducreyi, Moraxella catarrhalis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Neisseria gonlorhoeae s, Campella. anaerobic bacteria: Bacteroides fragilis.
Azithromycin is also active against Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis, Treponema pallidum.
It is also active against Toxoplasma gondii.
Pharmacokinetics
It is rapidly absorbed from the gastrointestinal tract. Food intake reduces the absorption of azithromycin. Cmax in plasma is achieved in 2-3 hours. It is rapidly distributed in tissues and biological fluids. 35% of azithromycin is metabolized in the liver by demethylation. More than 59% is excreted in the bile unchanged, about 4.5% - in the urine unchanged.
Side effects

From the digestive system: nausea, vomiting, flatulence, diarrhea, abdominal pain, a transient increase in the activity of liver enzymes; rarely cholestatic jaundice.
Allergic reactions: rarely - skin rash, angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Dermatological reactions: rarely - photosensitization.
From the side of the central nervous system: dizziness, headache; rarely - drowsiness, weakness.
From the hematopoietic system: rarely - leukopenia, neutropenia, thrombocytopenia.
From the side of the cardiovascular system: rarely - chest pain.
From the genitourinary system: vaginitis; rarely - candidiasis, nephritis, increased residual urea nitrogen.
Others: rarely - hyperglycemia, arthralgia.
Interaction

With simultaneous use with ergot alkaloids, the risk of developing ergotism cannot be excluded.
With the simultaneous use of azithromycin with warfarin, cases of enhancement of the effects of the latter are described.
With the simultaneous use of digoxin or digitoxin with azithromycin, a significant increase in the concentration of cardiac glycosides in the blood plasma and the risk of developing glycosidic intoxication are possible.
With simultaneous use with disopyramide, a case of ventricular fibrillation has been described.
With simultaneous use with lovastatin, cases of the development of rhabdomyolysis are described.
With simultaneous use with rifabutin, the risk of developing neutropenia and leukopenia increases.
With simultaneous use, the metabolism of cyclosporine is disrupted, which increases the risk of developing side and toxic reactions caused by cyclosporine.